Xencor
Monrovia, CA · Founded 2004 · CIK 0001326732 · Biotech · Public
Engineered monoclonal antibodies optimized for improved therapeutic efficacy using the XmAb protein engineering platform
xencor.com →- Grants
- —
- No SBIR or STTR on record
- Sector median: 1
- Raised
- $46M
- 4 Form D · Nov 2021
- 58 months since last filing
- Contracts
- —
- No federal contracts on record
- Patents
- 40
- 17 granted · 23 pending
- Sector median: 2
Capital Timeline
Federal ↑Equity ↓20082010201220142016201820202022
| Date | Event | Source | Amount |
|---|---|---|---|
| Private capital raised | Form D · SEC | $6,000,000 | |
| Private capital raised | Form D · SEC | $7,500,000 | |
| Private capital raised | Form D · SEC | $7,597,653 | |
| Private capital raised | Form D · SEC | $25,000,000 |
Form D · SEC
Peer position
| # | Company | Contracts | Disclosed equity |
|---|---|---|---|
| 2288 | MarvelBiome, Inc. | — | $55M |
| 2289 | Voyager Therapeutics | — | $119M |
| 2290 | Precision Fermentation, Inc. | — | $53M |
| 2291 | Xencor | — | $46M |
| 2292 | Perceive Biotherapeutics, Inc. | — | $40M |
| 2293 | HBVTECH | — | — |
| 2294 | Fortress Biotech, Inc. | — | $39M |
Ranked on federal contract value rather than capital raised. The equity column is the comparison worth making — companies at the same procurement position often sit at very different points in their funding history.
Founders & Team
- Esper BoelDirector
- Bruce CarterDirector
- Bassil DahiyatDirector · Executive Officer
- John DesjarlaisExecutive Officer
- Celia EckertExecutive Officer
- Douglas FambroughDirector
- Ellen FeigalDirector
- Jonathan FlemingDirector
- Donald FosterDirector
- Kevin GormanDirector
- Kurt GustafsonDirector
- Yujiro HataDirector
- John KuchExecutive Officer
- Richard LernerDirector
- Ben MachielseDirector
- A. MontgomeryDirector
- Timothy PearsonDirector
- Richard RanieriDirector
- Dagmar Rosa-BjorkesonDirector
- Atul SaranDirector
- John StaffordDirector
- Charles StewartDirector
- Harold WernerDirector
- Allen YangExecutive Officer
Patents
- METHODS FOR TREATING IgG4-RELATED DISEASESapplication
- Anti-human C5 Antibodiesapplication
- ANTI-CD28 Compositionsgranted
- Antigen Binding Domains That Bind To Mesothelin (msln)granted
- ANTI-TL1A x ANTI-IL23 ANTIBODIESapplication
- ANTI-CD28 X ANTI-TROP2 Antibodiesapplication
- ANTI-CD28 X Anti-msln Antibodiesapplication
- HETERODIMERIC HUMAN IgG1 POLYPEPTIDES WITH ISOELECTRIC POINT MODIFICATIONSgranted
- Heterodimeric Antibodies That Bind CD3 And GPC3granted
- Novel Heterodimeric Proteinsapplication
- Methods And Compositions For Inhibiting CD32B Expressing Cellsapplication
- NOVEL COMPOSITIONS AND METHODS FOR TREATING IgE-MEDIATED DISORDERSapplication
Regulatory activity · Biotech
- New Animal Drugs; Approval of New Animal Drug Applications; Withdrawal of Approval of New Animal Drug Application; Change of SponsorFood and Drug Administration
- Medical Devices; General and Plastic Surgery Devices; Classification of the Skin Patch for Treatment of HyperhidrosisFood and Drug Administration
- Medical Devices; Anesthesiology Devices; Classification of the Monitor for Opioid Induced Impairment of OxygenationFood and Drug Administration
- Medical Devices; Orthopedic Devices; Classification of the Medial Knee Implanted Shock AbsorberFood and Drug Administration
- Medical Devices; Neurological Devices; Classification of the External Lower Extremity Nerve Stimulator for Restless Legs SyndromeFood and Drug Administration
- Medical Devices; General Hospital and Personal Use Devices; Classification of the Infant Supine Sleep SystemFood and Drug Administration
Rules are matched to sector, not to company. Recent activity in a sector is context rather than a signal about this business — until rules are matched to what a company actually builds, the section is shown as context and nothing more.